文献速递前列腺癌

临床局限性高危前列腺癌根治性前列腺切除术后患者循环肿瘤细胞的识别与特征分析

Identification and Characterization of Circulating Tumor Cells in Men Who have Undergone Prostatectomy for Clinically Localized, High Risk Prostate Cancer.
PubMed 文献 · J Urol · 2019-09-06

研究对37例高危局限性前列腺癌根治术后2至5个月的患者采血,用商业平台计数循环肿瘤细胞并做配对肿瘤与单细胞测序;30/37例(81.1%)检出循环肿瘤细胞,中位2.4个/ml(范围0至22.9),可检出者复发时间呈缩短趋势(p=0.12),所有生化复发者均可检出循环肿瘤细胞。

要点

  • 根治术后2至5个月,37例高危局限性前列腺癌中30例(81.1%)检出循环肿瘤细胞。
  • 可检出循环肿瘤细胞者复发时间呈缩短趋势(p=0.12),所有生化复发者均可检出。
  • 生化复发者循环肿瘤细胞拷贝数畸变更多(p=0.027),配对测序显示异质性。

核心结论

  • 根治性前列腺切除术后循环肿瘤细胞检出率高,循环肿瘤细胞负荷更高、拷贝数畸变更多的患者生化复发时间更短。
  • 循环肿瘤细胞中可检出与前列腺癌已知拷贝数畸变一致的基因组改变,但常与原发性病灶批量分析细胞不一致。
  • 作者认为经适当把握度的队列进一步检测后,早期循环肿瘤细胞检测可能成为辅助治疗决策的有用生物标志物。

研究设计与样本

  • 研究纳入37例高危局限性前列腺癌患者,高危定义为分期T3a或更高、Gleason评分8分或更高、或前列腺特异抗原20 ng/ml或更高。
  • 根治性前列腺切除术后2至5个月采集血样,使用商业平台计数循环肿瘤细胞。
  • 进行配对的肿瘤组织与单个循环肿瘤细胞测序。

主要发现

  • 37份样本中30份(81.1%)检出循环肿瘤细胞,中位2.4个/ml(范围0至22.9)。
  • 可检出循环肿瘤细胞的患者复发时间呈缩短趋势(p=0.12)。
  • 所有生化复发患者均可检出循环肿瘤细胞。
  • 37例中7例(18.9%)检出雄激素受体过表达。
  • 生化复发患者循环肿瘤细胞拷贝数畸变更多(p=0.027)。

关键数值与推荐

  • 高危局限性前列腺癌定义:分期T3a或更高、Gleason评分8分或更高、或前列腺特异抗原20 ng/ml或更高。
  • 循环肿瘤细胞检出率30/37(81.1%),中位2.4个/ml(范围0至22.9)。
  • 可检出循环肿瘤细胞者复发时间缩短趋势p=0.12。
  • 生化复发者循环肿瘤细胞拷贝数畸变更多的p=0.027。
  • 雄激素受体过表达7/37(18.9%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 可检出循环肿瘤细胞者复发时间缩短仅为趋势(p=0.12),未达统计学显著。
  • 作者指出需在适当把握度的队列中进一步检测,早期循环肿瘤细胞检测才可能成为辅助治疗决策的有用生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Approximately 15% of men with newly diagnosed prostate cancer have high risk features which increase the risk of recurrence and metastasis. Better predictive biomarkers could allow for earlier detection of biochemical recurrence and change surveillance and adjuvant treatment paradigms. Circulating tumor cells are thought to represent the earliest form of metastases. However, their role as biomarkers in men with high risk, localized prostate cancer is not well defined. MATERIALS AND METHODS: Two to 5 months after prostatectomy we obtained blood samples from 37 patients with high risk, localized prostate cancer, defined as stage T3a or higher, Gleason score 8 or greater, or prostate specific antigen 20 ng/ml or greater. Circulating tumor cells were enumerated using a commercial platform. Matched tumor and single circulating tumor cell sequencing was performed. RESULTS: Circulating tumor cells were detected in 30 of 37 samples (81.1%) with a median of 2.4 circulating tumor cells per ml (range 0 to 22.9). Patients with detectable circulating tumor cells showed a trend toward shorter recurrence time (p=0.12). All patients with biochemical recurrence had detectable circulating tumor cells. Androgen receptor over expression was detected in 7 of 37 patients (18.9%). Patients with biochemical recurrence had more circulating tumor cell copy number aberrations (p=0.027). Matched tumor tissue and single circulating tumor cell sequencing revealed heterogeneity. CONCLUSIONS: We noted a high incidence of circulating tumor cell detection after radical prostatectomy and shorter time to biochemical recurrence in men with a higher circulating tumor cell burden and more circulating tumor cell copy number aberrations. Genomic alterations consistent with established copy number aberrations in prostate cancer were detectable in circulating tumor cells but often discordant with cells analyzed in bulk from primary lesions. With further testing in appropriately powered cohorts early circulating tumor cell detection could be an informative biomarker to assist with adjuvant treatment decisions.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Friedlander TW, Welty C, Anantharaman A, et al. Identification and Characterization of Circulating Tumor Cells in Men Who have Undergone Prostatectomy for Clinically Localized, High Risk Prostate Cancer. J Urol. 2019. PMID: 31216253. doi:10.1097/JU.0000000000000393

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。